Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha.

@article{Aicher1990ContrastenhancedMR,
  title={Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha.},
  author={K P Aicher and J W Dupon and David L. White and Sharon Lea Aukerman and Michael E. Moseley and Richard P Juster and Werner Rosenau and Jeffrey L. Winkelhake and Robert C. Brasch},
  journal={Cancer research},
  year={1990},
  volume={50 22},
  pages={7376-81}
}
Pharmacological effects of recombinant human tumor necrosis factor alpha (TNF) were studied in a mouse fibrosarcoma model using magnetic resonance imaging enhanced with a macromolecular contrast agent, albumin(gadolinium-diethylenetriamine pentaacetic acid)35. TNF was administered i.v. in a dose of 150 micrograms/kg, 60 to 80 min prior to imaging. Contrast-enhanced and nonenhanced magnetic resonance images of TNF-treated (n = 10) and untreated (n = 8) Meth A fibrosarcomas were obtained at 2.0… CONTINUE READING